There was one unanswered question in the highly anticipated anti-kickback proposed rules issued Oct. 9 by the Trump health agency: whether the medical device and drug industries get protections. For now, the answer is no.
The anti-kickback statute currently prohibits payments for recommending products or services to patients covered by Medicare or Medicaid and is meant to protect against fraud and abuse.
The Trump administration proposed several new safe harbors for doctors and hospitals to ease compliance barriers and encourage health providers to collaborate on patients’ overall health. The changes are intended to be the gateway to “value-based care,” which ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.